

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
29 December 2004 (29.12.2004)

PCT

(10) International Publication Number
WO 2004/113279 A1

(51) International Patent Classification⁷: **C07C 311/08**,
A61K 31/198, A61P 37/00, 29/00

(21) International Application Number:
PCT/EP2004/006553

(22) International Filing Date: 16 June 2004 (16.06.2004)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
0314488.8 20 June 2003 (20.06.2003) GB

(71) Applicant (for all designated States except US): **GLAXO
GROUP LIMITED** [GB/GB]; Glaxo Wellcome House,
Berkeley Avenue, Greenford Middlesex UB6 0NN (GB).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **HOLMES, Ian**
[GB/GB]; GlaxoSmithKline, Gunnels Wood Road, Stevenage
Hertfordshire SG1 2NY (GB). **WATSON, Stephen,**
Paul [GB/GB]; GlaxoSmithKline, Gunnels Wood Road,
Stevenage Hertfordshire SG1 2NY (GB).

(74) Agent: **GIDDINGS, Peter, John**; GlaxoSmithKline, Corporate
Intellectual Property (CN925.1), 980 Great West
Road, Brentford Middlesex TW8 9GS (GB).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN,
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI,
GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE,
KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD,
MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG,
PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM,
TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM,
ZW.


(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM,
ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),
European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI,
FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI,
SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ,
GW, ML, MR, NE, SN, TD, TG).

Published:

- with international search report
- before the expiration of the time limit for amending the
claims and to be republished in the event of receipt of
amendments

For two-letter codes and other abbreviations, refer to the "Guidance
Notes on Codes and Abbreviations" appearing at the beginning
of each regular issue of the PCT Gazette.

(54) Title: INHIBITORS OF MATRIX METALLOPROTEINASE



(57) Abstract: Compounds of formula (I), wherein R¹ represents optionally substituted C₄₋₁₂ alkyl, optionally substituted C₂₋₆alkylaryl, or optionally substituted 5- or 6- membered aryl or heteroaryl; Z represents a bond, CH₂, O, S, SO, SO₂, NR⁴, OCR⁴R⁵, CR⁴R⁵O, or Z, R¹ and Q together form an optionally substituted fused tricyclic group; Q represents an optionally substituted 5- or 6- membered aryl or heteroaryl ring; X represents COR³ or N(OR⁸)COR⁹; R² represents SO₂R¹⁰ or SO₂NR¹⁰R¹¹; R³ represents OR⁶, NR⁶R⁷ or NR⁶OH; R⁴ and R⁵ each independently represents H, C₁₋₆ alkyl or C₁₋₄ alkylaryl; R⁶ and R⁷ each independently represents H, C₁₋₆ alkyl, or C₁₋₆ alkyl substituted with one or more heteroaryl groups, or R⁶ and R⁷ together with the nitrogen atom to which they are attached form a 5- or 6- membered ring which may optionally include 1 or more further heteroatoms selected from O, S and N; R⁸ and R⁹ each independently represents H or C₁₋₆ alkyl; R¹⁰ and R¹¹ each independently represents H or C₁₋₆ alkyl; and physiologically functional derivatives thereof, with the exception of N-(ethoxycarbonyl)-N-[4-(1H-tetrazol-1-yl)phenyl]glycine, processes for their preparation, pharmaceutical formulations containing them and their use as inhibitors of matrix metalloproteinase enzymes (MMPs) are described.